Futura Medical Past Earnings Performance
Past criteria checks 0/6
Futura Medical has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings declining at 2.4% annually. Revenues have been growing at an average rate of 93.3% per year.
Key information
6.8%
Earnings growth rate
19.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 93.3% |
| Return on equity | -48.1% |
| Net Margin | -44.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Need To Know: Analysts Are Much More Bullish On Futura Medical plc (LON:FUM)
Sep 13
We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth
Apr 17Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation
Jan 05Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?
Jul 28We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully
Mar 18We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate
Sep 25Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation
May 10We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow
Jan 10What We Learned About Futura Medical's (LON:FUM) CEO Compensation
Dec 21
Revenue & Expenses Breakdown
How Futura Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 8 | -4 | 8 | 2 |
| 31 Mar 24 | 6 | -5 | 7 | 2 |
| 31 Dec 23 | 3 | -7 | 7 | 2 |
| 30 Sep 23 | 2 | -6 | 5 | 3 |
| 30 Jun 23 | 2 | -5 | 4 | 3 |
| 31 Mar 23 | 1 | -5 | 3 | 4 |
| 31 Dec 22 | 0 | -6 | 3 | 4 |
| 30 Sep 22 | 0 | -6 | 3 | 4 |
| 30 Jun 22 | 0 | -6 | 2 | 4 |
| 31 Mar 22 | 0 | -5 | 2 | 4 |
| 31 Dec 21 | 0 | -5 | 2 | 4 |
| 30 Sep 21 | 0 | -4 | 2 | 3 |
| 30 Jun 21 | 0 | -3 | 1 | 2 |
| 31 Mar 21 | 0 | -3 | 1 | 2 |
| 31 Dec 20 | 0 | -2 | 1 | 2 |
| 30 Sep 20 | 0 | -4 | 1 | 4 |
| 30 Jun 20 | 0 | -6 | 1 | 6 |
| 31 Mar 20 | 0 | -7 | 1 | 8 |
| 31 Dec 19 | 0 | -9 | 1 | 10 |
| 30 Sep 19 | 0 | -9 | 1 | 10 |
| 30 Jun 19 | 0 | -8 | 1 | 9 |
| 31 Mar 19 | 0 | -7 | 1 | 8 |
| 31 Dec 18 | 0 | -6 | 1 | 6 |
| 30 Sep 18 | 0 | -5 | 1 | 5 |
| 30 Jun 18 | 0 | -4 | 1 | 4 |
| 31 Mar 18 | 0 | -4 | 1 | 4 |
| 31 Dec 17 | 0 | -4 | 1 | 4 |
| 30 Sep 17 | 0 | -4 | 1 | 4 |
| 30 Jun 17 | 0 | -3 | 1 | 3 |
| 31 Mar 17 | 0 | -4 | 1 | 3 |
| 31 Dec 16 | 0 | -4 | 1 | 4 |
| 30 Sep 16 | 0 | -4 | 1 | 4 |
| 30 Jun 16 | 0 | -5 | 1 | 4 |
| 31 Mar 16 | 0 | -5 | 1 | 4 |
| 31 Dec 15 | 0 | -5 | 1 | 5 |
| 30 Sep 15 | 0 | -5 | 1 | 4 |
| 30 Jun 15 | 0 | -4 | 1 | 4 |
| 31 Mar 15 | 0 | -4 | 1 | 3 |
| 31 Dec 14 | 0 | -3 | 1 | 2 |
| 30 Sep 14 | 0 | -3 | 1 | 2 |
| 30 Jun 14 | 0 | -3 | 1 | 2 |
| 31 Mar 14 | 0 | -2 | 1 | 2 |
| 31 Dec 13 | 0 | -2 | 1 | 2 |
| 30 Sep 13 | 0 | -2 | 1 | 2 |
Quality Earnings: FUM is currently unprofitable.
Growing Profit Margin: FUM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FUM is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare FUM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FUM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4%).
Return on Equity
High ROE: FUM has a negative Return on Equity (-48.05%), as it is currently unprofitable.